December 2010 | Oncology & Biotech News

March 11, 2011

Medulloblastoma, a malignant brain tumor that most commonly affects children, is not one disease but several, said researchers with St. Jude Children's Hospital in Memphis, Tennessee.

March 09, 2011

The novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.

March 09, 2011

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.

March 09, 2011

Intensified immunochemotherapy with R-ACVBP significantly improved event-free survival, progression-free survival, disease-free survival, and overall survival compared with R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL), but at the cost of increased hematologic toxicity.

March 09, 2011

Carfilzomib, described as a next-generation protease inhibitor, produced durable responses in patients with multiple myeloma whose disease relapsed after or proved refractory to all available therapies.

March 09, 2011

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a pivotal phase II study involving younger patients with relapsed or refractory Hodgkin lymphoma.

March 09, 2011

Bosutinib (SKI-606) seems poised to join the tyrosine kinase inhibitors (TKIs) imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna) as a first-line therapy option for patients with chronic myelogenous leukemia in the chronic phase.

March 09, 2011

In patients with newly diagnosed multiple myeloma who are candidates for transplant, bortezomib (Velcade) achieved high complete response (CR) rates during induction, delayed disease progression, and improved overall survival (OS).

March 09, 2011

The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer.

March 09, 2011

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

March 09, 2011

The FDA has notified Spectrum Pharmaceuticals that it will decide whether to approve Fusilev (levoleucovorin) for colorectal cancer within 6 months.

March 09, 2011

The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.

March 09, 2011

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

March 09, 2011

An article in Oncogene further explains how ultraviolet (UV) radiation helps transform skin cells into basal cell carcinoma.

March 09, 2011

A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.

March 09, 2011

A Web-based CME program gives physicians in rural areas free access to clinical research and expert advice on oncology through an e-newsletter.

March 09, 2011

A retrospective study conducted at Stanford University found that the risk of cancer due to radiation from CT scans might be lower than previously determined.

March 09, 2011

Coloring for Chemo/Comfort is a nonprofit organization in Nevada started by Amy Villarele-Hardy and Nina Lawyer in November 2009.

March 09, 2011

According to the British Journal of Cancer, a new study by London's Institute of Cancer Research finds that finger length might be an indicator of prostate cancer risk.

March 09, 2011

PFN presents a quick snapshot financial news as it relates to recent drug developments, clinical trials, mergers and acquisitions, etc.

March 08, 2011

Researchers have ruled out race as a prognostic factor for overall survival (OS) in black patients with a lung cancer diagnosis.

March 08, 2011

Over the past 40 years, since the declaration of the War on Cancer in 1971, we have seen tremendous advances in our struggle with this deadly disease.

March 08, 2011

We have dedicated several pages of our final issue of 2010 to exploring the nearly 40 years that have elapsed since the National Cancer Act was signed in 1971.

March 08, 2011

Much has transpired in the 40 years since President Richard Nixon announced that finding a cure for cancer would be one of his administration's top priorities.